INTRODUCTION: We evaluated the gene expression levels of atrogin-1, MuRF1, myostatin, follistatin, activin A, and inhibin alpha in skeletal muscle samples of patients with gastric cancer and controls. METHODS: We studied 38 cancer patients and 12 controls who underwent surgery for gastric adenocarcinoma and benign abdominal diseases, respectively. A biopsy specimen was obtained from the rectus abdominis muscle from all participants. The relative gene expression of atrogin-1, MuRF1, myostatin, follistatin, activin A, and inhibin alpha was determined by quantitative real-time polymerase chain reaction analysis. RESULTS: Atrogin-1 and MuRF1 mRNA expression was similar between cancer patients and controls and was unaffected by the disease stage or the severity of body weight loss. Transcript levels of myostatin and follistatin did not differ between cases and controls and were similar across disease stages and categories of weight loss. Finally, no differences were detected in activin A and inhibin alpha gene expression between cancer patients and controls. CONCLUSIONS: In skeletal muscle, the gene expression of atrogin-1, MuRF1, myostatin, follistatin, activin A, and inhibin alpha is not affected by the presence of cancer. The expression of atrophy-related genes is unaffected by the disease stage and the degree of weight loss.
INTRODUCTION: We evaluated the gene expression levels of atrogin-1, MuRF1, myostatin, follistatin, activin A, and inhibin alpha in skeletal muscle samples of patients with gastric cancer and controls. METHODS: We studied 38 cancerpatients and 12 controls who underwent surgery for gastric adenocarcinoma and benign abdominal diseases, respectively. A biopsy specimen was obtained from the rectus abdominis muscle from all participants. The relative gene expression of atrogin-1, MuRF1, myostatin, follistatin, activin A, and inhibin alpha was determined by quantitative real-time polymerase chain reaction analysis. RESULTS:Atrogin-1 and MuRF1 mRNA expression was similar between cancerpatients and controls and was unaffected by the disease stage or the severity of body weight loss. Transcript levels of myostatin and follistatin did not differ between cases and controls and were similar across disease stages and categories of weight loss. Finally, no differences were detected in activin A and inhibin alpha gene expression between cancerpatients and controls. CONCLUSIONS: In skeletal muscle, the gene expression of atrogin-1, MuRF1, myostatin, follistatin, activin A, and inhibin alpha is not affected by the presence of cancer. The expression of atrophy-related genes is unaffected by the disease stage and the degree of weight loss.
Authors: Paul T Winnard; Santosh K Bharti; Marie-France Penet; Radharani Marik; Yelena Mironchik; Flonne Wildes; Anirban Maitra; Zaver M Bhujwalla Journal: Cancer Res Date: 2015-12-30 Impact factor: 12.701
Authors: Neil Johns; Shinji Hatakeyama; Nathan A Stephens; Martin Degen; Simone Degen; Wilfried Frieauff; Christian Lambert; James A Ross; Ronenn Roubenoff; David J Glass; Carsten Jacobi; Kenneth C H Fearon Journal: PLoS One Date: 2014-01-03 Impact factor: 3.240
Authors: Guohua Zhang; Lindsey J Anderson; Song Gao; Thomas K Sin; Zicheng Zhang; Hongyu Wu; Syed H Jafri; Solomon A Graf; Peter C Wu; Atreya Dash; Jose M Garcia; Yi-Ping Li Journal: Front Cell Dev Biol Date: 2021-12-07
Authors: Ana Anoveros-Barrera; Amritpal S Bhullar; Cynthia Stretch; Nina Esfandiari; Abha R Dunichand-Hoedl; Karen J B Martins; David Bigam; Rachel G Khadaroo; Todd McMullen; Oliver F Bathe; Sambasivarao Damaraju; Richard J Skipworth; Charles T Putman; Vickie E Baracos; Vera C Mazurak Journal: J Cachexia Sarcopenia Muscle Date: 2019-07-15 Impact factor: 12.063